Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022
Waltham, Mass., September 27, 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based
0 Comments
Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer
Waltham, Mass., August 23 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series